Pfizer reported strong quarterly results, exceeding Wall Street expectations with $14.7 billion in sales and $0.51 earnings per share. CEO Albert Bourla expressed satisfaction with the company's performance despite potential challenges from US policies aimed at lowering drug prices. President Trump announced upcoming tariffs on pharmaceuticals, which could impact the industry significantly. Teljes cikk (Euronews.com)